Announcements Trials

Browse Landscape

Phase

Phase 1/2 3 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 6 Small Cell Lung Carcinoma 4 Cholangiocarcinoma 4 Stomach Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Thyroid Neoplasms 2 Ovarian Neoplasms 2 Neuroendocrine Tumors 2 Carcinoma, Hepatocellular 2 Biliary Tract Neoplasms 2 Sarcoma 1 Refractory Metastatic Digestive System Carcinoma 1 Pulmonary Neuroendocrine Tumor 1 Pancreatic Cancer Metastatic 1 Osteosarcoma 1 Neoplasms 1 Neoplasm Metastasis 1 NSCLC 1 Locally Advanced Pancreatic Cancer 1 Head and Neck Cancers - Salivary Gland 1 Gallbladder Neoplasms 1 Differentiated Thyroid Cancer 1 Colorectal Neoplasms 1 Carcinoma, Neuroendocrine 1 Carcinoma 1 Breast Neoplasms 1 Appendiceal Neoplasms 1 Advanced Solid Tumors 1 Advanced Pancreatic Cancer 1 Advanced Non-Small Cell Lung Cancer 1

Interventions

Doxorubicin 62 Ifosfamide 39 Gemcitabine 29 Radiotherapy 27 Filgrastim 27 Cyclophosphamide 26 Docetaxel 19 Vincristine 18 pembrolizumab 17 Etoposide 17 pazopanib 16 Cisplatin 16 Nivolumab 15 Trabectedin 14 apatinib 13 Magnetic Resonance Spectroscopy 13 Carboplatin 12 Irinotecan 11 Bevacizumab 11 Temozolomide 10 Sirolimus 10 camrelizumab 9 anlotinib 9 Surgical Procedures, Operative 9 Sorafenib 9 Paclitaxel 9 Ipilimumab 9 Injections 9 Dactinomycin 9 Topotecan 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Sarcoma × surufatinib × Clear all

NCT05106777 2023-04-12

Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma

Sun Yat-sen University

Phase 2 Unknown

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡